AMS and Tracer Studies at GSK – A ripple or a wavefront?
Graeme Young – GSK: AMS – a ripple or a wavefront?
GSK publish on the use of AMS to determine the absolute bioavailability of dabrafenib, a BRAF inhibitor, in patients
"...AMS [is] an invaluable tool in our early drug development program, allowing us to quickly assess bioavailability in humans and focus resources on our most promising drug candidates going forward."
Find out how we can help you accelerate your drug-development program.